These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 25456870)

  • 1. Comparison of safety of left atrial catheter ablation procedures for atrial arrhythmias under continuous anticoagulation with apixaban versus phenprocoumon.
    Kaess BM; Ammar S; Reents T; Dillier R; Lennerz C; Semmler V; Grebmer C; Bourier F; Buiatti A; Kolb C; Deisenhofer I; Hessling G
    Am J Cardiol; 2015 Jan; 115(1):47-51. PubMed ID: 25456870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apixaban, Rivaroxaban, and Dabigatran in Patients Undergoing Atrial Fibrillation Ablation.
    Rillig A; Lin T; Plesman J; Heeger CH; Lemes C; Metzner A; Mathew S; Wissner E; Wohlmuth P; Ouyang F; Kuck KH; Tilz RR
    J Cardiovasc Electrophysiol; 2016 Feb; 27(2):147-53. PubMed ID: 26464027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of apixaban in the patients undergoing the ablation of atrial fibrillation.
    Nagao T; Inden Y; Shimano M; Fujita M; Yanagisawa S; Kato H; Ishikawa S; Miyoshi A; Okumura S; Ohguchi S; Yamamoto T; Yoshida N; Hirai M; Murohara T
    Pacing Clin Electrophysiol; 2015 Feb; 38(2):155-63. PubMed ID: 25487164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of continuous periprocedural rivaroxaban for patients undergoing left atrial catheter ablation procedures.
    Dillier R; Ammar S; Hessling G; Kaess B; Pavaci H; Buiatti A; Semmler V; Kathan S; Hofmann M; Lennerz C; Kolb C; Reents T; Deisenhofer I
    Circ Arrhythm Electrophysiol; 2014 Aug; 7(4):576-82. PubMed ID: 24970293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility and safety of uninterrupted periprocedural apixaban administration in patients undergoing radiofrequency catheter ablation for atrial fibrillation: Results from a multicenter study.
    Di Biase L; Lakkireddy D; Trivedi C; Deneke T; Martinek M; Mohanty S; Mohanty P; Prakash S; Bai R; Reddy M; Gianni C; Horton R; Bailey S; Sigmund E; Derndorfer M; Schade A; Mueller P; Szoelloes A; Sanchez J; Al-Ahmad A; Hranitzky P; Gallinghouse GJ; Hongo RH; Beheiry S; Pürerfellner H; Burkhardt JD; Natale A
    Heart Rhythm; 2015 Jun; 12(6):1162-8. PubMed ID: 25728754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation.
    Di Biase L; Callans D; Hæusler KG; Hindricks G; Al-Khalidi H; Mont L; Cosedis Nielsen J; Piccini JP; Schotten U; Kirchhof P
    Europace; 2017 Jan; 19(1):132-138. PubMed ID: 28130378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of Uninterrupted Apixaban Therapy Versus Warfarin During Atrial Fibrillation Ablation.
    Shah RR; Pillai A; Schafer P; Meggo D; McElderry T; Plumb V; Yamada T; Kumar V; Doppalapudi H; Gunter A; Pentecost E; Maddox WR
    Am J Cardiol; 2017 Aug; 120(3):404-407. PubMed ID: 28595862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of Uninterrupted Periprocedural Edoxaban Versus Phenprocoumon for Patients Who Underwent Left Atrial Catheter Ablation Procedures.
    Kottmaier M; Bourier F; Pausch H; Reents T; Semmler V; Telishevska M; Koch-Büttner K; Lennerz C; Lengauer S; Kornmayer M; Rousseva E; Brooks S; Brkic A; Ammar-Busch S; Kaess B; Dillier R; Grebmer C; Kolb C; Hessling G; Deisenhofer I
    Am J Cardiol; 2018 Feb; 121(4):445-449. PubMed ID: 29289359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial.
    Flaker G; Lopes RD; Hylek E; Wojdyla DM; Thomas L; Al-Khatib SM; Sullivan RM; Hohnloser SH; Garcia D; Hanna M; Amerena J; Harjola VP; Dorian P; Avezum A; Keltai M; Wallentin L; Granger CB;
    J Am Coll Cardiol; 2014 Oct; 64(15):1541-50. PubMed ID: 25301455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of pre-procedural interrupted apixaban on heparin anticoagulation during catheter ablation for atrial fibrillation: a prospective observational study.
    Bin Abdulhak AA; Kennedy KF; Gupta S; Giocondo M; Ramza B; Wimmer AP
    J Interv Card Electrophysiol; 2015 Nov; 44(2):91-6. PubMed ID: 26292959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apixaban, rivaroxaban, and dabigatran use in patients undergoing catheter ablation for atrial fibrillation using the second-generation cryoballoon.
    Tscholl V; Lsharaf AK; Lin T; Bellmann B; Nagel P; Lenz K; Landmesser U; Roser M; Rillig A
    Clin Cardiol; 2017 Nov; 40(11):1095-1099. PubMed ID: 28846806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Prospective Randomized Trial of Apixaban Dosing During Atrial Fibrillation Ablation: The AEIOU Trial.
    Reynolds MR; Allison JS; Natale A; Weisberg IL; Ellenbogen KA; Richards M; Hsieh WH; Sutherland J; Cannon CP
    JACC Clin Electrophysiol; 2018 May; 4(5):580-588. PubMed ID: 29798783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apixaban for periprocedural anticoagulation during catheter ablation of atrial fibrillation: a systematic review and meta-analysis of 1691 patients.
    Blandino A; Bianchi F; Biondi-Zoccai G; Grossi S; Conte MR; Rametta F; Gaita F
    J Interv Card Electrophysiol; 2016 Sep; 46(3):225-36. PubMed ID: 27217030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Total Incidence of Complications and the Impact of an Anticoagulation Regime on Adverse Events After Cryoballoon Ablation of Atrial Fibrillation: A Single-Center Study of 409 Patients.
    Koektuerk B; Turan CH; Yorgun H; Keskin K; Schoett M; Dahmen A; Gorr E; Yang A; Hoppe C; Horlitz M; Turan RG
    Cardiovasc Ther; 2016 Jun; 34(3):144-51. PubMed ID: 26880220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apixaban versus Warfarin for the Prevention of Periprocedural Cerebral Thromboembolism in Atrial Fibrillation Ablation: Multicenter Prospective Randomized Study.
    Kuwahara T; Abe M; Yamaki M; Fujieda H; Abe Y; Hashimoto K; Ishiba M; Sakai H; Hishikari K; Takigawa M; Okubo K; Takagi K; Tanaka Y; Nakajima J; Takahashi A
    J Cardiovasc Electrophysiol; 2016 May; 27(5):549-54. PubMed ID: 26766541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes.
    Hylek EM; Held C; Alexander JH; Lopes RD; De Caterina R; Wojdyla DM; Huber K; Jansky P; Steg PG; Hanna M; Thomas L; Wallentin L; Granger CB
    J Am Coll Cardiol; 2014 May; 63(20):2141-2147. PubMed ID: 24657685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation).
    Flaker G; Lopes RD; Al-Khatib SM; Hermosillo AG; Hohnloser SH; Tinga B; Zhu J; Mohan P; Garcia D; Bartunek J; Vinereanu D; Husted S; Harjola VP; Rosenqvist M; Alexander JH; Granger CB;
    J Am Coll Cardiol; 2014 Mar; 63(11):1082-7. PubMed ID: 24211508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial.
    Held C; Hylek EM; Alexander JH; Hanna M; Lopes RD; Wojdyla DM; Thomas L; Al-Khalidi H; Alings M; Xavier D; Ansell J; Goto S; Ruzyllo W; Rosenqvist M; Verheugt FW; Zhu J; Granger CB; Wallentin L
    Eur Heart J; 2015 May; 36(20):1264-72. PubMed ID: 25499871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry.
    Lakkireddy D; Reddy YM; Di Biase L; Vallakati A; Mansour MC; Santangeli P; Gangireddy S; Swarup V; Chalhoub F; Atkins D; Bommana S; Verma A; Sanchez JE; Burkhardt JD; Barrett CD; Baheiry S; Ruskin J; Reddy V; Natale A
    J Am Coll Cardiol; 2014 Mar; 63(10):982-8. PubMed ID: 24412445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Left atrial thrombus and dense spontaneous echocardiographic contrast in patients on continuous direct oral anticoagulant therapy undergoing catheter ablation of atrial fibrillation: Comparison of dabigatran, rivaroxaban, and apixaban.
    Wu M; Gabriels J; Khan M; Shaban N; D'Amato S; Liu CF; Markowitz SM; Ip JE; Thomas G; Singh P; Lerman B; Patel A; Cheung JW
    Heart Rhythm; 2018 Apr; 15(4):496-502. PubMed ID: 29605015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.